{"entity":{"id":"blueprint-medicines","kind":"company","name":"Blueprint Medicines","aka":[],"tldr":"Blueprint Medicines invented Ayvakit, a pill approved for systemic mastocytosis and for a rare gut tumour called GIST that carries a specific mutation. The French drug maker Sanofi bought the company in 2025.","summary":"Blueprint Medicines is a Cambridge, Massachusetts kinase medicine company, now a Sanofi company. Its approved product, Ayvakit/Ayvakyt (avapritinib), is a KIT and PDGFRA inhibitor approved for advanced and indolent systemic mastocytosis and, per the company's site, for certain gastrointestinal stromal tumours (GIST). The pipeline includes elenestinib, a next-generation KIT inhibitor for systemic mastocytosis, and BLU-808, an oral wild-type KIT inhibitor for mast cell-driven allergic and inflammatory disease. Sanofi and Blueprint announced a definitive agreement on 2 June 2025 at 129 US dollars per share in cash (about 9.1 billion US dollars equity value) plus a contingent value right of up to 6 US dollars per share; the tender offer expired on 17 July 2025 with about 70.9 percent of shares tendered, and the merger was completed the same day, ending the Nasdaq listing. Blueprint's former Nasdaq ticker was BPMC.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.blueprintmedicines.com/"},{"label":"Sanofi acquisition announcement (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925055143/tm2516831d1_ex99-1.htm"},{"label":"Tender offer completion 8-K (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1597264/000119312525160804/d909980d8k.htm"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["kit"],"drugs":["pralsetinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07629960"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and IPO (2015) not sourced. The company website blocked curl (Cloudflare) but was fetched successfully with WebFetch. The GIST indication statement rests on the website summary; the Sanofi release frames the deal around systemic mastocytosis and immunology. The completion date (17 July 2025) is stated in Blueprint's Form 8-K reporting completion of the merger."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.blueprintmedicines.com/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2025,"amountUsd":9100000000,"source":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925055143/tm2516831d1_ex99-1.htm","note":"129 US dollars per share in cash (equity value about 9.1 billion) plus a contingent value right worth up to 6 US dollars per share for BLU-808 milestones; tender offer and merger completed 17 July 2025"}],"acquiredBy":"sanofi"},"route":"/companies/blueprint-medicines/","neighbours":{"cancer":[{"id":"ret-fusion-nsclc","kind":"cancer","name":"RET fusion-positive non-small-cell lung cancer","route":"/cancers/ret-fusion-nsclc/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"}],"drug":[{"id":"pralsetinib","kind":"drug","name":"Pralsetinib","route":"/drugs/pralsetinib/"}],"trial":[{"id":"nct07629960","kind":"trial","name":"A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations","route":"/trials/nct07629960/"},{"id":"arrow-thyroid","kind":"trial","name":"ARROW (thyroid cohorts)","route":"/trials/arrow-thyroid/"},{"id":"explorer","kind":"trial","name":"EXPLORER","route":"/trials/explorer/"},{"id":"navigator","kind":"trial","name":"NAVIGATOR","route":"/trials/navigator/"},{"id":"voyager","kind":"trial","name":"VOYAGER","route":"/trials/voyager/"}],"company":[{"id":"boxer-capital","kind":"company","name":"Boxer Capital","route":"/companies/boxer-capital/"},{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/"}]}}